Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine
In present study the immediate and long-term therapy results of 14 patients with refractory chronic lymphocytic leukemia (CLL) are analyzed. Treatment program included alemtuzumab alone or in combination with fludarabine.
Saved in:
| Main Authors: | E. V. Kataeva, A. K. Golenkov, E. V. Trifonova, G. A. Dudina, T. A. Mitina, L. L. Vysotskaya, T. D. Lutskaya, I. V. Buravtsova, R. V. Gorenkov, Yu. Yu. Chuksina, V. V. Yazdovskiy |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-07-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/95 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Alemtuzumab in treatment of chronic lymphocytic leukemia
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01) -
Lower Number of Fludarabine Cycles in Patients with Lymphoid Malignancies
by: Donald Pasquale
Published: (2014-08-01) -
IMMUNE AND CYTOKINE STATUS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING ALEMTUZUMAB
by: M. N Khorobrykh, et al.
Published: (2014-07-01) -
Clinical management of alemtuzumab-induced autoimmune thyroid diseases: a narrative review
by: Jacopo Manso, et al.
Published: (2025-06-01) -
The role of alemtuzumab in the development of secondary autoimmunity in multiple sclerosis: a systematic review
by: Sofia Jimenez-Sanchez, et al.
Published: (2024-11-01)